|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA
B by Suppression of Rac1 and Inhibitor of
B Kinase 
Center for Clinical Research, Department of Anesthesiology, University Hospital Freiburg, Freiburg, Germany (M.H., H.D., P.S., U.G., M.R., R.S., C.I.S., T.L., K.K.G., H.L.P.); Department of Medicine IV and Kidney Research Center Cologne, University of Cologne, Cologne, Germany (N.A.); and Department of Anesthesiology, University Hospital Duesseldorf, Duesseldorf, Germany (B.H.J.P.)
Thionamides, inhibitors of the thyroid peroxidase-mediated iodination, are clinically used in the treatment of hyperthyroidism. However, the use of antithyroid drugs is associated with immunomodulatory effects, and recent studies with thionamide-related heterocyclic thioderivates demonstrated direct anti-inflammatory and immunosuppressive properties. Using primary human T-lymphocytes, we show that the heterocyclic thionamides carbimazole and propylthiouracil inhibit synthesis of the proinflammatory cytokines tumor necrosis factor (TNF)
and interferon (IFN)
. In addition, DNA binding of nuclear factor (NF)-
B, a proinflammatory transcription factor that regulates both TNF
and IFN
synthesis, and NF-
B-dependent reporter gene expression were reduced. Abrogation of NF-
B activity was accompanied by reduced phosphorylation and proteolytic degradation of inhibitor of
B (I
B)
, the inhibitory subunit of the NF-
B complex. Carbimazole inhibited NF-
B via the small GTPase Rac-1, whereas propylthiouracil inhibited the phosphorylation of I
B
by its kinase inhibitor of
B kinase
. Methimazole had no effect on NF-
B induction, demonstrating that drug potency correlated with the chemical reactivity of the thionamide-associated sulfur group. Taken together, our data demonstrate that thioureylenes with a common, heterocyclic structure inhibit inflammation and immune function via the NF-
B pathway. Our results may explain the observed remission of proinflammatory diseases upon antithyroid therapy in hyperthyroid patients. The use of related thioureylenes may provide a new therapeutic basis for the development and application of anti-inflammatory compounds.
Address correspondence to: Dr. Matjaz Humar, Center for Clinical Research, Breisacher Strasse 66, D-79106 Freiburg, Germany. E-mail: humar{at}ana1.ukl.uni-freiburg.de
This article has been cited by other articles:
![]() |
M. M. Glatstein, F. Garcia-Bournissen, N. Giglio, Y. Finkelstein, and G. Koren Pharmacologic treatment of hyperthyroidism during lactation Can Fam Physician, August 1, 2009; 55(8): 797 - 798. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Humar, C. Graetz, M. Roesslein, U. Goebel, K. K. Geiger, B. Heimrich, and B. H. J. Pannen Heterocyclic Thioureylenes Protect from Calcium-Dependent Neuronal Cell Death Mol. Pharmacol., March 1, 2009; 75(3): 667 - 676. [Abstract] [Full Text] [PDF] |
||||